Those in the CBT-I group who experienced sustained remission of insomnia had significant lowering of p16INK4a gene expression while those in the control group who had sustained insomnia over the 2-year interval exhibited increases in p16INK4a. This evidence concerns the gene CDKN2A and insomnia.